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ABSTRACT Hepatocyte-stimulating factor, interferon-
B2, B-cell stimulation factor 2, and hybridoma/plasmacytoma
growth factor are identical proteins presently referred to as
interleukin 6 (IL-6). Through the use of synthetic oligonucle-
otide technology, we have constructed a biologically active
recombinant IL-6 (rIL-6) gene based on the sequence of a
human IL-6 cDNA. The synthetic gene encodes a cysteine-free,
bioengineered rIL-6 protein that is expressed at high levels in
Escherichia coli as a tripartite fusion protein. Cleavage of the
fusion protein with collagenase releases a 23-kDa rIL-6 protein
that can be easily purified to homogeneity. We show that the
rIL-6 protein displays a range of biological activities similar to
those of natural human IL-6, as demonstrated by its ability to
(i) protect cells from viral infection, (ii) stimulate the synthesis
of fibrinogen in rat FAZA 967 cells, and (iii) induce the
terminal differentiation of B cells, resulting in elevated secre-
tion of immunoglobulin.
Interleukin 6 (IL-6) is a member of the rapidly growing list of
multifunctional human cytokines. This factor, originally
identified as interferon-182 (IFN-f32; ref. 1) and the 26-kDa
protein (2), was first detected in poly(I)-poly(C)-stimulated
human fibroblasts. It was shown by direct DNA sequence
comparison that B-cell stimulation factor 2 (BSF-2; ref. 3), a
potent T-cell-derived lymphokine, and B-cell hybridoma/
plasmacytoma growth factor (4, 5), a fibroblast-derived
protein, are also identical to IL-6/IFN-132. In addition, a third
protein, hepatocyte-stimulating factor (HSF; ref. 6), has also
been shown to share functional and immunological identity
with IFN-fl2.
In addition to its well-documented function as B-cell
stimulator (5), other studies have demonstrated that IL-6, in
synergy with IL-3, supports the proliferation of hematopoi-
etic progenitor cells (7). As HSF, IL6 modulates the synthesis
of a subset of liver-derived proteins in response to injury and
infection (6). Other facets ofIL-6 activity include interactions
with IL-1, tumor necrosis factor (6, 8, 9), IFN-,81, and
platelet-derived growth factor (9) and the stimulation of
corticotropin release from pituitary cells (10). The multiplic-
ity of actions suggests that IL-6 plays a role in a complex
cytokine network needed for homeostatic control of cellular
functions (9).
Several laboratories have cloned and expressed IL-6 in
mammalian and bacterial cells (1, 3, 11). These reports
indicate, however, that considerable expense, time, and
effort are required to purify small quantities of the recombi-
nant protein. We present here the construction of a modified
bacterial expression plasmid capable of producing large
amounts of a synthetic, biologically active form of IL-6. Our
protein, which lacks the four cysteine residues found in
native human IL-6, is produced in Escherichia coli, can easily
and rapidly be purified to homogeneity, and exhibits a range
of activities similar to native IL-6.
MATERIALS AND METHODS
Construction of the Gene for the IL-6-Like Protein. The
oligonucleotides used to construct the gene for IL-6-like
protein were synthesized by using 8-cyanoethyl phosphor-
amidites obtained from American Bionetics (Hayward, CA)
and purified by reverse-phase HPLC. Assembly of the
oligomers was carried out in three steps. Complementary
oligonucleotides averaging 54 bases in length were annealed
in pairs, gel purified, and ligated as described (12). For DNA
amplification, each fragment was cloned separately into a
pBS M13+ cloning vector (Stratagene, La Jolla, CA) modi-
fied by insertion of a 28-base oligonucleotide adapter (5'-
AGCTTCCATGGTCGCGACTCGAGCTGCA-3'), which
added Nco I, Nru I, and Xho I sites between the HindIII and
Pst I sites of the multiple cloning region. Cloning of the DNA
produced recombinants p333, p334, p331, and p332 (Fig. 1).
All DNA manipulations were performed according to stan-
dard procedures (13). DNA was sequenced by the chain-
termination method (14).
The final assembly led to the construction of p337, which
contained the complete coding sequence of rIL-6, including
the termination codon, inserted between the Nco I and EcoRI
sites of the modified pBS M13+ vector. In order to express
the rIL-6-,8-galactosidase fusion protein, the Bgl II-EcoRI
fragment contained in p337 was replaced with a pair of
annealed oligonucleotides in which the rIL-6 stop codon was
changed to serine (p365; Fig. 1).
Construction of the Recombinant Expression Vector. The
vector used for expression of the synthetic IL-6-like protein
was derived from pJG200 constructed by Germino and Bastia
(15). This modified vector, p340, contains the hybrid-in-
ducible promoter P-trc of pKK233-2 (Pharmacia) in place of
the phage A PR promoter. In addition, a minicistron sequence,
which has been reported to increase levels of protein expres-
sion in E. coli (16), has been inserted between the P-trc
promoter and the initiating methionine. The remainder of the
vector is composed of pJG200 plasmid sequences. The rIL-6
gene from p365 was inserted between the Nco I and BamHI
sites ofp340, resulting in the expression vector p367. The size
of the insert was confirmed by minilysate DNA extraction
followed by polyacrylamide gel electrophoresis. Expression
of the rIL-6-p-galactosidase fusion protein was indepen-
Abbreviations: BSF, B-cell stimulation factor; HSF, hepatocyte-
stimulating factor; IL, interleukin; IFN, interferon; PMA, phorbol
12-myristate 13-acetate; r, recombinant; SRBC, sheep erythro-
cyte; pfc, plaque-forming colonies.
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FIG. 1. Assembly of the recombinant IL-6 (rlL-6) gene. Oligonucleotides were annealed and ligated to yield the four synthetic
double-stranded fragments of the rIL-6 gene. The insert contained in p333 was formed by ligating two pairs of complementary oligonucleotides,
each bearing internal 5-base 5' complementary overhangs (nucleotides 59-63, Fig. 2). Construct p334 was composed of three pairs of annealed
oligonucleotides joined at residues 162-167 and 220-225. Complementary overhangs for the assembly of p331 were located at nucleotides 312-
315 and 358-361. Construct p332 was ligated at positions 457-461 and 512-517. Synthetic fragments were cloned into a modified pBS M13+
vector (p287) by insertion into the multiple cloning site by means of synthetic 4- to 6-base overhangs (represented by dotted or hatched boxes).
The coding sequence of the rIL-6 gene is shown in black. Open boxes represent p287 sequences. Removal of the termination codon (*) in p337
was accomplished by substituting a second synthetic fragment containing a serine residue and a compatible EcoRI overhang (RI). Nucleotide
564 identifies the position of the last base contained in the Bgl II site fusing the insert in p365 with the collagen linker of the expression vector.
Restriction sites are as follows: B, BamHI; Bg, Bgl II; RI, EcoRI; RV, EcoRV; H, Hindlll; N, Nco I; S, Stu I; X, Xba I.
dently verified by electrophoretic transfer blot (Western blot)
analysis of a total E. coli lysate using an anti-p-galactosidase
monoclonal antibody obtained from Promega Biotec.
Growth and Purification. Transformed JM101 cells con-
taining plasmid p367 were grown in 10-liter batch cultures
using a Magnaferm fermentor (New Brunswick Scientific).
Cells were grown in 2x YT medium (16 g of tryptone/10 g of
yeast extract/5 g of NaCl per liter and 10 mM KH2PO4, pH
7.5) containing 100 ,ug of ampicillin per ml and induced at A550
= 1.5 by addition of isopropyl P-D-thiogalactopyranoside
(Sigma) to 5 mM. Cells were harvested within 12 hr, pelleted
by centrifugation at 5000 x g, and stored at -20°C until
needed. E. coli cells were processed in aliquots of 100 g (wet
weight) by washing with TNS buffer (30 mM Tris HCI, pH
7.4/30 mM NaCI/0.05% sodium lauroyl sarcosine), followed
by lysis in 450 ml ofTNS buffer containing 1.5 mM EDTA and
0.5 mg of lysozyme per ml. Complete lysis was ensured by
subjecting cells to three cycles of freeze-thawing and brief
sonication. Soluble proteins, devoid of f3-galactosidase ac-
tivity, were removed by three repeated washings in TNS
buffer followed by centrifugation. The final pellet, weighing
-40 g, was resuspended in 60 ml of 10% sodium lauroyl
sarcosine and diluted to 2.4 liters with phosphate-buffered
saline (1.6 mM KH2PO4/10 mM Na2HPO4/150 mM NaCI).
Insoluble material was removed by centrifugation and the
supernatant was made 40% with ammonium sulfate. Precip-
itated protein contained in the final extract was resuspended
in 250 ml of20mM Tris HCI, pH 7.4/150mM NaCl and stored
frozen.
One unit of collagenase purified from Achromobacter
iophagus (EC 3.4.24.8; Boehringer Mannheim) was dissolved
in 100 ,u of buffer containing 100 mM Tris HCl (pH 7.4), 250
mM NaCI, 1 mM CaC12, and 40 ,g ofp-hydroxymercuriben-
zoate per ml to reduce nonspecific proteolysis associated
with this enzyme (17). Thawed extract (4 ml) was sonicated
briefly to disperse aggregates, added to the pretreated col-
lagenase, and incubated for 45 min at room temperature. The
majority of the cleaved 8-galactosidase was removed by
adding 0.5 vol of saturated ammonium sulfate and pelleting
the insoluble material. The cleaved rIL-6 was recovered by
increasing the ammonium sulfate to 70% and centrifuging to
compact the insoluble protein into a floating pellicle. The
pellicle was resuspended in 0.5 ml of Tris-buffered saline
prior to the addition of an equal volume of 60% acetonitrile/
0.1% trifluoroacetic acid for purification by reverse-phase
HPLC. The concentration and purity of the rIL-6 were
determined by NaDodSO4/PAGE under reducing conditions
followed by Coomassie staining and scanning laser densi-
tometry (LKB; UltroScan XL). The identity of the HPLC-
purified material was confirmed by direct amino acid se-
quencing using an Applied Biosystems 475A protein se-
quencer.
Viral Plaque Reduction Assay. Antiviral activity of rIL-6
was determined by a plaque reduction assay adapted to use
on microtiter plates. Cells of the transformed human epithe-
lial cell line HEp-2 (ATCC no. CCL 23) were grown in
Dulbecco's modified Eagle's medium (DMEM)/F-12 me-
dium, 10% calf serum, and antibiotics. Monolayers were
treated with serial dilutions of rIL-6 12 hr prior to vesicular
stomatitis virus challenge. After treatment, cells were in-
fected at a multiplicity of infection of 1.0. At 24 hr after
infection, cells were stained with neutral red (18). Controls
consisted of untreated infected cells and uninfected cells.
Standards included rIFN-,61 (obtained through the Biological
Response Modifier Program, National Institutes of Health,
Bethesda, MD) and cell culture supernatant obtained from
phorbol 12-myristate 13-acetate (PMA)-stimulated human
diploid fibroblasts (MRC-5; ATCC no. CCL 171). Colorimet-
ric determinations were evaluated using a Vmax ELISA plate
reader (Molecular Devices, Palo Alto, CA).
Hepatocyte Stimulation Assay. FAZA 967 rat hepatoma
cells (19) were grown in DMEM/F-12 medium supplemented
with 10% NuSerum (Collaborative Research, Waltham,
MA), penicillin, and streptomycin. Assays were performed
on 1-day-old confluent monolayers seeded in 48-well plates
(Costar, Cambridge, MA). Prior to treatment with rIL-6 and
other conditioned media, cells were washed with serum-free
medium containing 0.1 ,M dexamethasone. Treated cells
were subsequently maintained in serum-free/dexamethasone
medium for the duration of the assay. Cells were incubated
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in the presence of rIL-6 and other conditioned media for 5 hr
at 370C in a tissue culture incubator. Fibrinogen levels were
determined by solid-phase ELISA as described (20) using a
1:1000 dilution of rabbit anti-rat fibrinogen polyclonal anti-
serum (obtained from Gerald R. Crabtree, Stanford Univer-
sity). Secondary antibody was affinity-purified alkaline phos-
phatase-conjugated goat anti-rabbit antiserum (Promega Bio-
tec). Bound antibody was visualized by addition of substrates
nitroblue tetrazolium and 5-bromo-4-chloro-3-indoylphos-
phate, p-toluidine salt (Sigma). Positive controls consisted of
cells treated with supernatant obtained from PMA-stimulated
MRC-5 fibroblasts. Quantitation of the assay was carried out
by scanning laser densitometry.
B-Cell Differentiation Assay. Murine B-cell clone CH12.LX
(/i+, V', Ly-1) was grown and maintained in RPMI 1640
medium containing 5% heat-inactivated fetal bovine serum,
300 gg of glutamine per ml, 0.04 mM 2-mercaptoethanol, and
antibiotics. CH12.LX cells bear surface IgM specific for the
phosphatidylcholine moiety of sheep erythrocytes (SRBCs;
ref. 21). The differentiation assay was performed by culturing
2 x 105 B cells in the presence of various concentrations of
rIL-6 in 2 ml of B-cell medium in Costar 24-well plates.
SRBCs (ASA Biological Products, Winston-Salem, NC)
were washed three times in RPMI 1640 medium prior to use;
1 x 106 erythrocytes were included in each test culture.
Positive controls consisted of mitogen-stimulated B cells
using 50 ug of lipopolysaccharide per ml (Difco). Cultures
were incubated at 370C in an atmosphere of 5% CO2 in air.
Direct hemolytic plaque-forming colonies (pfc) in CH12.LX
cultures were determined as described (22).
RESULTS
Synthesis and Expression of rIL-6. The coding sequence
used for the expression of rIL-6, based on the cDNA
sequence of human IL-6 (3), was constructed using 22
synthetic oligonucleotides. Subsets of these were assembled
to produce four fragments, each representing approximately
one fourth of the rIL-6 coding sequence (Fig. 1). Inserts were
subsequently combined to yield the entire coding sequence of
the rIL-6 gene shown in Fig. 2.
Nucleotide sequence modifications, designed to introduce
novel restriction sites for use in joining the gene fragments,
10 30 so
were incorporated within the coding sequence as silent
mutations. The introduction of synthetic in-frame Nco I sites
(constructs p333 and p331) enabled visual confirmation of
reading frame integrity during assembly by blue/white assay
in the presence of isopropyl f3-D-thiogalactopyranoside and
5-bromo-4-chloro-3-indolyl /3-D-galactoside. Other modifica-
tions, shown in Fig. 2, were introduced to optimize expres-
sion and include (i) replacement of the terminal 118-
nucleotide signal sequence normally found in the native IL-6
gene with a methionine codon (nucleotides 3-5) to avoid
difficulties associated with the processing of a eukaryotic
signal sequence; (ii) replacement ofthe Pio residue in the native
sequence (3) with G2ly (nucleotides 6-8) in the rIL-6 sequence
to facilitate removal of the initiating methionine by E. coli; (iii)
replacement of the normal stop codon with a serine codon to
effect fusion of the rIL-6 protein with the collagen linker; and
(iv) replacement of the four internal cysteine residues with
serines to circumvent complications associated with disulfide
bond formation in E. coli.
Expression of the synthetic rIL-6 gene was achieved by
subcloning the coding sequence into a modified expression
vector that directs the synthesis of a tripartite protein
composed of rIL-6, a 60-amino acid collagen linker, and
,B-galactosidase (15).
Purification of rIL-6. Enzymatic activity of the ,B-
galactosidase, assayed using the chromogenic substrate o-
nitrophenol ,B-D-galactoside, was found to associate almost
exclusively with the insoluble fraction of the bacterial cell
lysate (Fig. 3, lane 1). Thus, 60% of all contaminating cellular
material could be removed by repeated washes of the insol-
uble E. coli lysate fraction. A large proportion of the fusion
protein was dissociated from the insoluble fraction in the
presence of detergent and further purified by repeated
ammonium sulfate precipitation to yield a preparation con-
taining 40% fusion protein (Fig. 3, lane 2).
Collagenase digestion of the partially purified lysate re-
sulted in the disappearance ofthe 130-kDa fusion product and
its replacement with two smaller bands of 100 kDa and 23 kDa
(Fig. 3, lane 3). Densitometric scanning of the collagenase-
treated lysate, electrophoresed under reducing conditions on
a 10% polyacrylamide/NaDodSO4 gel, showed that the
decrease in intensity of the 130-kDa band could be accounted
70 90
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FIG. 2. Complete nucleotide sequence (5' -* 3')
of the synthetic rIL-6 gene and its predicted amino
acid sequence. The coding sequence of the fused
gene begins at nucleotide 3 (Met). The amino acid
sequence of the rIL-6 protein extends to nucleotide
557 (Met), where it is fused to the collagen linker of
the fusion protein by means of a serine residue. The
asterisk designates the location of the TAG stop
codon normally found in the native cDNA sequence
(3). Modified amino acid residues are shown in
script below the sequence.
Proc. Natl. Acad. Sci. USA 85 (1988)
Proc. Natl. Acad. Sci. USA 85 (1988) 9429








FIG. 3. NaDodSO4/PAGE analysis of rIL-6 protein purification.
Samples were electrophoresed on 10% polyacrylamide/NaDodSO4
gels under reducing conditions. Lanes: 1, crude E. coli lysate; 2,
partially purified fusion protein after washing, ammonium sulfate
precipitation, and solubilization in 10% detergent; 3, collagenase
digestion of detergent-solubilized material showing the 23-kDa rIL-6
band; 4, partial purification of rIL-6 by differential protein precipi-
tation and recovery in 70% ammonium sulfate; 5, reverse-phase
HPLC purification of rIL-6; M, protein molecular mass markers
(shown in kDa).
for by the appearance of the 100-kDa and 23-kDa proteins.
Addition of ammonium sulfate to 40% saturation selectively
precipitated most of the released P-galactosidase. Electro-
phoretic analysis of recovered material following a second
precipitation with 70% ammonium sulfate is shown in Fig. 3,
lane 4. The rIL-6 protein, purified to homogeneity by HPLC,
eluted from the column at 54% acetonitrile as a single peak
(Fig. 3, lane 5). The slight heterogeneity in molecular size of
the band shown in lane 5 is probably due to the presence of
multiple collagenase-sensitive cleavage sites within the col-
lagen linker (15). The estimated molecular mass of 23 kDa
suggests that no more than 15 collagen residues are present
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FIG. 4. (A) Antiviral activity of cysteine-free rIL-6. HEp-2 cells
(1 x 105 cells per well) were incubated for 8-10 hr with the indicated
concentrations of rIL-6. Vesicular stomatitis virus was added to
treated cells (multiplicity of infection, 1.0) and incubated for an
additional 24 hr. Neutral red was added to washed monolayers,
removed after 2 hr, and extracted from washed cells with 50%
phosphate-buffered ethanol/water. Optical density on the y axis
reflects the ability of infected cells to sequester the vital stain. (B)
Stimulation of fibrinogen synthesis by rIL-6. Confluent FAZA cell
monolayers were treated with varying concentrations of purified
rIL-6 in the presence of 0.1 gM dexamethasone. After 5 hr of
stimulation, cell medium was filtered through a nitrocellulose mem-
brane using a dot-blot apparatus. Secreted fibrinogen levels were
determined by solid-phase immunoassay; concentrations were de-
rived by scanning laser densitometry and comparison of signal
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FIG. 5. B-cell differentiation assay. CH12.LX cells (2 x 105 cells
per well) were cocultured in the presence (0) or absence (0) of
antigen (SRBCs) prior to treatment with various concentrations of
rIL-6 as shown. After 48 hr, treated CH12.LX aliquots were mixed
with a freshly washed suspension of SRBCs containing guinea pig
complement and transferred to Cunningham chambers (22) for
incubation at 37'C. After 30 min, cells were returned to room
temperature, allowing hemolytic plaques to develop. The back-
ground level (2000 pfc) of differentiated B cells in the absence of
rIL-6, with and without antigen priming, is shown on the y axis.
Bacterial lipopolysaccharide, used as a positive control, gave a
response of 10,726 pfc per million cells. The results shown represent
mean values of duplicate assays. In all cases, individual points were
within 16% or less of their respective means.
HPLC-purified material was subjected to direct N-terminal
automated protein sequencing. Seven cycles of sequential
degradation produced the mixed sequence MG, GV, VP, P,
PG, GE, ED. This result suggests that the terminal methio-
nine residue is present on some but not all rIL-6 proteins. A
comparison of the amino acid peak areas demonstrated that
less than one-half of the soluble rIL-6 protein carried a
terminal methionine residue.
Virus Plaque Reduction. Specific activities for antiviral levels
of IL-6 obtained by mRNA microinjection of frog oocytes or
cell-free translation (23, 24) and by expression of recombinant
cDNA (1) range from 1 x 107 units/mg of protein to 1 x 102
units/mg. A 50% reduction in the viable cell number was
observed by using the cysteine-free rIL-6 at a concentration of
-0.01 ,tM (Fig. 4A). No protection was elicited when cells were
treated with normal E. coli lysate or with non-rIL-6-containing
fractions. By comparison with the IFN standard, the results
obtained led to a calculated specific IFN activity for rIL-6 of 1
x 104 international units/mg of protein.
Hepatocyte Stimulation. The rat hepatoma FAZA 967 cell
line was treated with varying concentrations of purified
recombinant protein. As shown in Fig. 4B, rIL-6 was capable
of inducing a 5-fold increase in fibrinogen levels within 5 hr
after treatment. From these results, we estimate the concen-
tration needed for half-maximal stimulatory activity to be
0.015 /iM.
B-Cell Differentiation. We examined the effect of rIL-6 on
cells of the SRBC-specific murine B-cell clone CH12.LX
(21). A maximal 6-fold stimulation of IgM production was
observed in the presence of antigen at a molar concentration
of 4.35 x 10-11 (Fig. 5). In the absence of antigen, however,
only a 2-fold increase in the numbers of pfc was detected.
These results are consistent with previous findings (reviewed
in ref. 25) demonstrating that IL-6 acts upon antigen- or
mitogen-activated B cells as opposed to resting B cells. No
proliferation of CH12.LX cells was observed in the presence
of rIL-6 (data not shown).
DISCUSSION
We have constructed a modified, biologically active IL-6-like
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(3). The synthetic rIL-6 gene was adapted for expression in
E. coli by (i) designing an efficient vector to suit our need for
high-level expression, (ii) introducing appropriate amino acid
sequence modifications to optimize bacterial expression of
the synthetic gene, and (iii) adding restriction sites necessary
for proper assembly of the gene fragments without changing
the amino acid sequence of the protein. Our initial attempts
to express rIL-6 directly were unsuccessful, as were efforts
to express it as a secreted periplasmic protein using the
alkaline phosphatase (phoA) signal sequence (26). It is
possible that the insolubility of the recombinant protein may
have contributed to the low level of expression of the
nonfused gene. On the other hand, synthesis of rIL-6 as a
fusion protein may serve to protect the recombinant material
from degradation (26).
In agreement with previous findings that indicated that
IL-6 extracted from reducing NaDodSO4/polyacrylamide
was capable of activating B cells in culture (11), we have
found that the removal of the cysteine residues did not seem
to significantly affect the biological properties of rIL-6. It is
interesting to note that the antiviral and hepatocyte-
stimulating activities of rIL-6 occur at concentrations of 0.01
AuM, equivalent to specific activities on the order of 104
units/mg of protein. May et al. (27) have also detected
antiviral and hepatocyte-stimulating activity with their
recombinant IL-6 and report specific activities in both cases
of 106 uhits/mg of protein. Whether the 100-fold difference
observed between these estimates is due to experimental
conditions or to the removal of the cysteine residues is not
clear; however, the consistent difference between these
reported values certainly merits further investigation. With
respect to hepatocyte stimulation, the level of fibrinogen
synthesis observed in FAZA cells is similar to the maximal
response observed using crude conditioned medium obtained
from PMA-induced fibroblasts (data not shown). This sug-
gests that the removal of the internal cysteine residues has a
limited effect on the functional integrity of IL-6.
To assess the ability of rIL-6 to induce immunoglobulin
secretion in B cells at the cellular level, a hemolytic plaque
assay was preferred over an immunoglobulin secretion assay
(28). Both methods have been used interchangeably to assay
for B-cell differentiation in response to various cytokines,
including IL-6 (29). The maximal stimulatory concentration
of about 0.1 ng/ml (43 pM) is in agreement with values
published elsewhere for IL-6 (11, 25) and suggests that re-
moval of the cysteine residues has no effect on the Il-cell
activity of rIL-6. At concentrations above 43 pM, rIL-6
causes a decrease in the number of differentiated B cells. A
similar effect occurs in the hepatocyte stimulation assay at
concentrations above 1 AM (data not shown). Although
toxicity of rIL-6 at high concentrations cannot be ruled out,
it is possible that excessive secretion of IgM in the B-cell
assay leads to excessive levels of antibody, resulting in a
prozone phenomenon (28). Another explanation is that rIL-6
may be involved in the isotype or class switching of secretory
antibodies as are IL-4 and IFN-y (30).
The retention of biological activity following the removal of
cysteine residues suggests that the primary sequence of rIL-6
contains the information necessary to fold the peptide chain
into an active conformation. This inherent stability serves to
make rIL-6 a suitable substrate for protein structure-function
studies. We are now in a position to selectively alter discrete
regions of the gene sequence using site-specific oligonucle-
otide mutagenesis to characterize further those determinants
that are responsible for stimulatory activity.
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